Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.
Cora N. Sternberg
No relevant relationships to disclose
Gedske Daugaard
No relevant relationships to disclose
Lajos Geczi
No relevant relationships to disclose
Sebastien J. Hotte
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Research Funding - Janssen
Paul N. Mainwaring
Consultant or Advisory Role - Janssen; Roche; Sanofi
Honoraria - Janssen; Roche; Sanofi
Fred Saad
Consultant or Advisory Role - Astellas Pharma; Janssen
Honoraria - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Janssen
Ciro Souza
Consultant or Advisory Role - Janssen; Pfizer
Miah Hiang Tay
No relevant relationships to disclose
Jose Manuel Tello Garrido
No relevant relationships to disclose
Luca Galli
No relevant relationships to disclose
Anil Londhe
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Peter De Porre
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen; Johnson & Johnson
Dan Atlan
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Betty Goon
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Emma Lee
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Tracy McGowan
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Vahid Naini
Employment or Leadership Position - Janssen
Mary Beth Todd
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Arturo Molina
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Daniel J. George
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Research Funding - Janssen